Choppy Week in Healthcare with Drug Pricing Issues Yet Again: Update-2-SELL-OFF
Update-2 10:45a 4/17...XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1...NASDAQ ekes out small gains but large cap biotechs take another hit with IBB down 1% to...
Biotech Hits New Highs for 2019:The Trends are Bullish…Update-3 at Sell-Off
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and "affordability board." See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks broadly down on. "Red Screen Day". 4/11/19...
High Volatility Among Individual stocks with Few Trends…Update-4
Update-4. 4/3 11:45A... Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3 4/2/19... Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91% NTLA 4.9% MGTX up 4.6%, etc. Most Mid-Caps green: BPMC up...
Biotech Green Screen: Sketchy Recovery is Underway…Update-3
Update-3...3/29 1:15p EDT. Biotech stocks catching bids today after a choppy week of trading. We will recap our top small cap picks from the JPM Conference after the close: AMRN, GNMK and TDOC. BIIB up again to 237. CELG up over 7% as prospects for BMY deal look good. ====== Update -2......
Biopharma Stocks Rally and Gene Therapy Stocks Are Still Hot (Not?)…Update-2
Update -2 March 24...Concerns about global growth, an inverted TSY yield curve and the German 10 year bond yield dropping below 10% triggered a major sell-off on Friday.The Russell 2000 dropped 3.62%. and the XBI dropped 4.62%. For the week ending 3/22: the XBI was down 4.3%, IBB down 5.3%, FBT...